Literature DB >> 36248297

Effect of Crocus sativus L. (Saffron) on Selected Cardiometabolic Traits in Healthy Young Men.

Wissal Abassi1, Nejmeddine Ouerghi1,2, Nidhal Jebabli1, Moncef Feki2, Anissa Bouassida1.   

Abstract

Entities:  

Year:  2022        PMID: 36248297      PMCID: PMC9529744          DOI: 10.18502/ijph.v51i7.10103

Source DB:  PubMed          Journal:  Iran J Public Health        ISSN: 2251-6085            Impact factor:   1.479


× No keyword cloud information.

Dear Editor-in-Chief

In this paper, we report the effect of acute saffron (SAF) dose on selected cardiometabolic traits in healthy young men. SAF, the dried red-orange stigmas of Crocus sativus L. is a small perennial plant derived from the Iridaceae family. This herb is native to Iran. The most essential bioactive components of SAF are picrocrocin, crocin and flavonoids (1). It has been applied in traditional medicine as anti-depressant, analgesic, anticonvulsant, anti-inflammatory, antioxidant, and anti-diabetic agent (2). Cardiovascular protective effects of SAF and its constituents have been investigated in several human trials (3). However, the majority of studies affect clinical patients such as subjects with metabolic syndrome and type 2 diabetes using chronic SAF administration (4). To the best of our knowledge, no studies have evaluated the acute SAF effect in healthy subjects. In the present study, we investigated the effect of single SAF supplementation on systolic (SBP) and diastolic (DBP) blood pressures, as well as blood glucose (BG) and heart rate (HR) in healthy active youths. Forty-four active young males (mean ± SD: age, 21.0±1.41 yr.; height, 1.75±0.09 m; body mass, 71.0±8.69 kg; body mass index, 23.2±2.13 kg/m2) volunteered in a double blind randomized study. Soft capsules identical in their appearance were filled with 300 mg SAF powder or 300 mg lactose powder by a pharmacist. An independent investigator allocated participants to SAF or lactose as placebo (PLB) with one-week washout period. Blood pressure, HR and BG were measured after two hours of SAF and PLA sessions (5) using an arm tensiometer (Exacto KD 591, Biosynex, France), heart rate monitor (Polar, Lake Succes, NY) and blood glucose monitor (Accu-Check Performa, Roche, Germany), respectively. The study was fully approved by the local Ethics Committee of High Institute of Sports and Physical Education of Kef (UR13JS01), conducted in accordance with the Helsinki Declaration and a signed informed consent was provided by all participants before study admission. SBP (121±4.82 vs. 119±3.42 mm.Hg, P=0.009) was significantly lower after SAF intake in comparison with PLB intake. However, no significant differences were observed for HR (97.57±4.52 vs. 96.89±4.71 batt/min, P=0.276), DBP (77.09±2.17 vs. 76.77±1.98 mm.Hg, P =0.430) and BG (0.93±0.05 vs. 0.93±0.04 g/L, P=0.819) in PLB session compared to SAF. Our results demonstrated that acute SAF reduce blood pressure, but has no significant effect on HR and BG. Available studies had used prolonged SAF intake and had demonstrated that chronic SAF reduced blood pressure in patients with type 2 diabetes (4) and in healthy subjects (6). We consider that blood pressure lowering effect of SAF might be explained by its inhibitory effects on heart rate and contractility and vasodilatory effects (7). Chronic intake of SAF or its components reduce blood glucose in diabetic rats (8). Moreover, a human study showed the hypoglycemic effect of SAF extract in clinical patients (9). The hypoglycemic effect of SAF extract seems to be performed by stimulation of glucose uptake and inhibition of intestinal glucose absorption (10). In summary, the present study provides evidence that nutritional SAF reduce blood pressure in healthy subjects. These findings suggest that SAF might be useful in hypertension.
  8 in total

Review 1.  New applications and mechanisms of action of saffron and its important ingredients.

Authors:  S Zahra Bathaie; S Zeinab Mousavi
Journal:  Crit Rev Food Sci Nutr       Date:  2010-09       Impact factor: 11.176

2.  Safety evaluation of saffron (Crocus sativus) tablets in healthy volunteers.

Authors:  Mohammad-Hadi Modaghegh; Masoud Shahabian; Habib-Allah Esmaeili; Omid Rajbai; Hossein Hosseinzadeh
Journal:  Phytomedicine       Date:  2008-08-06       Impact factor: 5.340

Review 3.  Clinical Applications of Saffron (Crocus sativus) and its Constituents: A Review.

Authors:  M Moshiri; M Vahabzadeh; H Hosseinzadeh
Journal:  Drug Res (Stuttg)       Date:  2014-05-21

4.  LC-DAD-MS (ESI+) analysis and antioxidant capacity of crocus sativus petal extracts.

Authors:  Aikaterini Termentzi; Eugene Kokkalou
Journal:  Planta Med       Date:  2008-04-10       Impact factor: 3.352

5.  The effect of saffron (Crocus sativus L.) supplementation on blood pressure, and renal and liver function in patients with type 2 diabetes mellitus: A double-blinded, randomized clinical trial.

Authors:  Fatemeh Ebrahimi; Naheed Aryaeian; Naseh Pahlavani; Davood Abbasi; Agha Fatemeh Hosseini; Soudabeh Fallah; Nariman Moradi; Iraj Heydari
Journal:  Avicenna J Phytomed       Date:  2019 Jul-Aug

6.  The Effect of Chronic Administration of Saffron (Crocus sativus) Stigma Aqueous Extract on Systolic Blood Pressure in Rats.

Authors:  Mohsen Imenshahidi; Bibi Marjan Razavi; Ayyoob Faal; Ali Gholampoor; Seyed Mehran Mousavi; Hossein Hosseinzadeh
Journal:  Jundishapur J Nat Pharm Prod       Date:  2013-11-01

7.  Evaluation of lung and bronchoalveolar lavage fluid oxidative stress indices for assessing the preventing effects of safranal on respiratory distress in diabetic rats.

Authors:  Saeed Samarghandian; Reza Afshari; Aghdas Sadati
Journal:  ScientificWorldJournal       Date:  2014-02-20

8.  Effect of crocin, a carotenoid from saffron, on plasma cholesteryl ester transfer protein and lipid profile in subjects with metabolic syndrome: A double blind randomized clinical trial.

Authors:  Ali Javandoost; Asma Afshari; Irandokht Nikbakht-Jam; Mohammad Khademi; Saied Eslami; Mina Nosrati; Mojtaba Foroutan-Tanha; Amirhossein Sahebkar; Shima Tavalaie; Majid Ghayour-Mobarhan; Gordon Ferns; Farzin Hadizadeh; Abolghasem Tabassi; Ahmad Mohajeri
Journal:  ARYA Atheroscler       Date:  2017-09
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.